Exhibit 99.1
|
|
Sent via Electronic Delivery to: angela@virios.com
May 24, 2023
Ms. Angela Walsh
Senior Vice President of Finance and Corporate Secretary Virios Therapeutics, Inc.
44 Milton Avenue
Alpharetta, GA 30009
Re: | Virios Therapeutics, Inc. (the “Company”) |
Dear Ms. Walsh:
On November 1, 2022, Staff notified the Company that its common stock failed to maintain a minimum bid price of $1.00 over the previous 30 consecutive business days as required by the Listing Rules of The Nasdaq Stock Market. Since then, Staff has determined that for the last 10 consecutive business days, from May 10, 2023 to May 23, 2023, the closing bid price of the Company’s common stock has been at $1.00 per share or greater. Accordingly, the Company has regained compliance with Listing Rule 5550(a)(2) and this matter is now closed.
If you have any questions, please contact Patryk Muter, at +1 301 532 6389.
Sincerely,
Ellen Ignacio
Nasdaq Listing Qualifications
| |
| |
|
|
